Skip to main content

Table 2 Ki-67 index variability and WHO class change in patients with multiple pathology specimens

From: Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study

Patient #

Primary tumor site Site1#

Metastatic/Re-biopsy tumor site Site2#

Ki-67 index (%)

Survival time

WHO class change

Site1#

Site2#

1

pancreas

peritoneum

70

70

12

2

pancreas

lymph node

10

30

15

G2 → G3

3

pancreas

peritoneum

5

20

6

G2 → G2

4

pancreas

liver

5

5

11

5

pancreas

liver

2

2

12

6

pancreas

pancreas

1

1

24

7

pancreas

liver

1

1

38

8

rectum

lymph node

70

70

12

9

rectum

liver

50

80

16

G3 → G3

10

rectum

liver

2

5

13

G1 → G2

11

rectum

liver

2

1

5

G1 → G1

12

rectum

liver

2

5

3

G1 → G2

13

rectum

lymph node

70

90

8

G3 → G3

14

rectum

lymph node

2

5

7

G1 → G2

15

rectum

liver

2

2

14

16

rectum

liver

10

10

17

rectum

rectum

80

60

12

G3 → G3

18

rectum

lymph node

60

80

G3 → G3

19

stomach

lymph node

2

5

12

G1 → G2

20

stomach

lymph node

60

80

14

G3 → G3

21

stomach

liver

1

1

24

22

stomach

lymph node

60

40

22

G3 → G3

23

stomach

lymph node

5

5

27

24

stomach

stomach

50

80

G3 → G3

25

stomach

stomach

70

30

33

G3 → G3

26

stomach

stomach

30

40

21

G3 → G3

27

stomach

pancreas

70

70

8

28

stomach

stomach

5

5

60

29

ileocecal junction

lymph node

70

70

16

30

duodenum

liver

5

5

12